Chiasma, Inc. (CHMA) Misses Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. DOX
5. CRWD
6. CHKP
7. ON
8. HNGE
9. INSP
10. SPY

Go back to Chiasma, Inc. (CHMA) Misses Q1 EPS by 8c

Chiasma Reports First Quarter 2016 Results

May 11, 2016 4:01 PM EDT

WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a biopharmaceutical company developing an investigational new drug, Mycapssa (octreotide) capsules, for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.

Based on the interest we have seen for an oral somatostatin analog and our clinical data to date, we continue to believe that Mycapssa has the potential to help many patients living with acromegaly, said Mark Leuchtenberger, president and chief executive officer of Chiasma. ... More